855 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
TEVA Teva Pharmaceutical Industries Limited $23.43 $23.86B N/A
Article Searches
Teva Selloff: A Wakeup Call? https://seekingalpha.com/article/4243234-teva-selloff-wakeup-call?source=feed_tag_israel Feb 22, 2019 - Teva has shown problems in generating earnings for its investors.My gap analysis shows that Teva is unlikely to recover quickly after the earnings selloff.Teva has high levels of debt, which is concer
Is 2019 The Trough For Teva, Or Will 2020 Continue To See Pressure? https://seekingalpha.com/article/4242739-2019-trough-teva-will-2020-continue-see-pressure?source=feed_tag_israel Feb 20, 2019 - After showing several years of resilience, competition is finally starting to eat away at Teva’s Copaxone and ProAir revenue.Investors and management expect Ajovy and Austedo to make up much of the lo
Stocks making the biggest moves premarket: CVS Health, Garmin, Gannett, Apple & more https://www.cnbc.com/2019/02/20/stocks-making-the-biggest-moves-premarket-cvs-health-garmin-gannett-apple--more.html Feb 20, 2019 - Names on the move ahead of the open.
Allergan Responds to Investor's Call for CEO/Chair Role Split http://www.zacks.com/stock/news/355578/allergan-responds-to-investors-call-for-ceo-chair-role-split?cid=CS-ZC-FT-355578 Feb 20, 2019 - Allergan (AGN) informs that it does not agree with the view of its key shareholder, Appaloosa, to separate the roles of CEO and board chairman.
Teva settlement with FTC resolves all litigation https://seekingalpha.com/news/3434802-teva-settlement-ftc-resolves-litigation?source=feed_news_all Feb 19, 2019 - Teva Pharmaceutical Industries (NYSE:TEVA) has settled with the Federal Trade Commission to resolve all outstanding litigation. That includes the FTC dropping claims against Teva and affiliates acros
Lilly wins review of Teva migraine patents in U.S. https://seekingalpha.com/news/3434551-lilly-wins-review-teva-migraine-patents-u-s?source=feed_news_all Feb 19, 2019 - The USPTO's Patent Trial and Appeal Board has agreed to review two patents (Nos. 9,340,614 and 9,226,951) covering Teva Pharmaceutical Industries' (TEVA -0.3%) migraine med AJOVY (fremenezumab).Compet
Teva Is Cheap And It Can Get Cheaper https://seekingalpha.com/article/4242115-teva-cheap-can-get-cheaper?source=feed_tag_israel Feb 19, 2019 - Since the acquisition of Actavis, Teva's balance sheet and cash flow were destroyed. It now has focused relentlessly on realigning its strategy and restoring the balance sheet.Halfway through now, it
Teva Pharmaceutical Industries Ltd (TEVA) Files 10-K for the Fiscal Year Ended on December 31, 2018 http://www.gurufocus.com/news/818602/teva-pharmaceutical-industries-ltd-teva-files-10k-for-the-fiscal-year-ended-on-december-31-2018 Feb 19, 2019 - Teva Pharmaceutical Industries Ltd (TEVA) Files 10-K for the Fiscal Year Ended on December 31, 2018, Stocks: TEVA, release date:Feb 19, 2019
Teva sees 25% of EpiPen market by year end https://seekingalpha.com/news/3434256-teva-sees-25-percent-epipen-market-year-end?source=feed_news_all Feb 19, 2019 - Teva Pharmaceutical (NYSE:TEVA) expects its generic version of Mylan's (NASDAQ:MYL) EpiPen to have about 25% share of the U.S. market by the end of 2019.The company is already selling its product for
What's in the Cards for Amarin (AMRN) This Earnings Season? http://www.zacks.com/stock/news/355196/whats-in-the-cards-for-amarin-amrn-this-earnings-season?cid=CS-ZC-FT-355196 Feb 18, 2019 - Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the fourth quarter.

Pages: 1...56789101112131415...86

<<<Page 10>